Bristol Myers Squibb ($BMY) multiple myeloma drug cut progression risk in late-stage trial
Bristol Myers Squibb reported positive Phase 3 results for experimental multiple myeloma therapy mezigdomide, strengthening its next-generation oncology pipeline as the company prepares for increased generic competition to key legacy…